Your browser is no longer supported. Please, upgrade your browser.
Rain Therapeutics Inc.
Index- P/E- EPS (ttm)- Insider Own19.60% Shs Outstand20.82M Perf Week7.67%
Market Cap388.99M Forward P/E- EPS next Y-2.21 Insider Trans43.80% Shs Float15.19M Perf Month-2.96%
Income- PEG- EPS next Q-0.48 Inst Own87.80% Short Float5.45% Perf Quarter-15.19%
Sales- P/S- EPS this Y-93.40% Inst Trans4.63% Short Ratio14.44 Perf Half Y-7.88%
Book/sh7.92 P/B1.86 EPS next Y11.60% ROA- Target Price25.25 Perf Year-
Cash/sh6.24 P/C2.36 EPS next 5Y- ROE- 52W Range11.57 - 23.90 Perf YTD-6.71%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-37.99% Beta-
Dividend %- Quick Ratio18.60 Sales past 5Y- Gross Margin- 52W Low28.09% ATR1.08
Employees17 Current Ratio18.60 Sales Q/Q- Oper. Margin- RSI (14)52.13 Volatility5.92% 7.57%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.68 Prev Close14.74
ShortableYes LT Debt/Eq0.00 EarningsAug 10 AMC Payout- Avg Volume57.27K Price14.82
Recom1.50 SMA204.65% SMA50-4.69% SMA200-11.79% Volume28,407 Change0.54%
Sep-14-21Resumed Goldman Neutral $22
Jul-20-21Initiated Piper Sandler Overweight $25
May-18-21Initiated Piper Sandler Overweight $25
May-18-21Initiated Guggenheim Buy $26
May-18-21Initiated Goldman Buy $56
May-18-21Initiated Citigroup Buy $28
Oct-25-21 08:00AM  
Oct-21-21 10:50AM  
Oct-07-21 10:00AM  
Oct-04-21 08:00AM  
Sep-29-21 08:47AM  
Sep-22-21 08:00AM  
Sep-17-21 07:47PM  
Sep-09-21 08:00AM  
Sep-08-21 08:00AM  
Sep-01-21 08:00AM  
Aug-11-21 02:11PM  
Aug-10-21 08:00AM  
Aug-03-21 08:00AM  
Jul-23-21 06:46AM  
Jul-20-21 08:00AM  
Jun-03-21 08:00AM  
Jun-02-21 08:00AM  
May-27-21 08:00AM  
May-25-21 08:00AM  
May-24-21 10:19AM  
May-20-21 08:00AM  
May-07-21 07:54PM  
Apr-23-21 12:07PM  
Apr-22-21 07:03PM  
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is RAIN-32, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing RAIN-32 that has completed Phase II clinical trial in liposarcoma, Phase I clinical trial in solid tumors, and Phase II clinical trial in intimal sarcoma, as well as RAD52 for tumors, including breast, ovarian, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PERCEPTIVE ADVISORS LLC10% OwnerOct 12Sale13.407,30697,9002,487,019Oct 13 05:47 PM
PERCEPTIVE ADVISORS LLC10% OwnerOct 11Sale12.5121,826273,0402,494,325Oct 13 05:47 PM
PERCEPTIVE ADVISORS LLC10% OwnerOct 08Sale13.157,50098,6212,516,151Oct 13 05:47 PM
PERCEPTIVE ADVISORS LLC10% OwnerOct 07Sale14.8113,368197,9182,523,651Oct 13 05:47 PM
BERGER FRANKLIN MDirectorSep 21Buy14.303,78654,140840,326Sep 23 05:21 PM
BVF PARTNERS L P/ILDirectorSep 21Buy13.9411,033153,8291,479,460Sep 23 08:05 PM
BVF PARTNERS L P/ILDirectorSep 13Buy16.49392,2696,468,5161,473,119Sep 15 05:23 PM
BVF PARTNERS L P/ILDirectorJul 06Buy15.25269,7234,113,2761,259,873Jul 06 07:34 PM
BVF PARTNERS L P/ILDirectorJul 01Buy15.65317,2794,965,4161,113,757Jul 06 07:34 PM
BVF PARTNERS L P/ILDirectorMay 24Buy15.901,36121,633941,300May 25 08:31 PM
BVF PARTNERS L P/ILDirectorMay 21Buy15.94121,9861,944,701940,581May 25 08:31 PM
BVF PARTNERS L P/ILDirectorMay 13Buy14.2658,000827,167761,537May 17 08:43 PM
PERCEPTIVE ADVISORS LLC10% OwnerApr 27Buy17.00550,0009,350,0002,537,019Apr 27 07:30 PM
Cormorant Asset Management, LPFormer 10% OwnerApr 27Buy17.00450,0007,650,0002,776,657Apr 29 04:02 PM
Davis Aaron I.DirectorApr 27Buy17.001,025,00017,425,0001,175,000Apr 27 05:09 PM
Boxer Capital, LLCDirectorApr 27Buy17.001,025,00017,425,0001,175,000Apr 27 05:11 PM
Boxer Capital, LLCDirectorApr 23Buy16.16150,0002,423,250150,000Apr 27 05:11 PM
Davis Aaron I.DirectorApr 23Buy16.16150,0002,423,250150,000Apr 27 05:09 PM
BERGER FRANKLIN MDirectorApr 23Buy16.95125,0002,118,900125,000Apr 27 05:05 PM